Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:38:11 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:ALLK from 2023-05-04 to 2024-05-03 - 12 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-14 16:02U:ALLKNews ReleaseAllakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-26 07:02U:ALLKNews ReleaseAllakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
2024-02-12 07:02U:ALLKNews ReleaseAllakos Announces Publication Highlighting AK006 Mast Cell Inhibition
2024-01-16 07:02U:ALLKNews ReleaseAllakos Announces a Restructuring to Focus on Development of AK006
2024-01-16 07:00U:ALLKNews ReleaseAllakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
2023-11-13 16:02U:ALLKNews ReleaseAllakos Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-08-30 16:05U:ALLKNews ReleaseAllakos Appoints Neil Graham to its Board of Directors
2023-08-09 16:02U:ALLKNews ReleaseAllakos Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-08-02 16:05U:ALLKNews ReleaseAllakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
2023-06-12 07:02U:ALLKNews ReleaseAllakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
2023-06-05 07:02U:ALLKNews ReleaseAllakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
2023-05-09 16:02U:ALLKNews ReleaseAllakos Provides Business Update and Reports First Quarter 2023 Financial Results